Covishield Approval
- All
- News
- Videos
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covishield Booster At Rs 600 Plus Tax: Adar Poonawalla To NDTV
Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covid Vaccines Covishield, Covaxin Get Conditional Market Approval: Report
India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.
-
An Approval That Suggests Big Changes In Booster Policy Are Likely
Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after
-
Covishield, Covaxin Cleared For Market Approval By Expert Panel
An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said
-
With 1.25 Billion Jabs, Adar Poonawalla's Covishield Seeks Full Clearance
Adar Poonawalla's Serum Institute Of India has applied to the country's drug regulator and the health ministry for full approval of its COVID-19 vaccine Covishield, the chief executive said on Friday.
-
Drug Regulator Seeks More Data Over Approval For Covishield Booster: Report
An expert panel of India's central drug authority reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday.
-
Central Drug Regulator Approves Shelf Life Of COVID-19 Vaccines CoviShield, Covaxin, ZyCoV-D
The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.
-
'Awaiting Lifting Of Curbs...': New Zealand's Nod To Covaxin, Covishield
New Zealand has included Covaxin and Covishield to its list of eight approved vaccines, Indian High Commissioner to the country, Mukhtesh Pardeshi, said today.
-
Covishield, Covaxin Recognised By 96 Countries, Says Health Minister
Union Health Minister Mansukh Mandaviya said on Tuesday that 96 countries have recognised Covaxin and Covishield and both these COVID-19 vaccines have received emergency use listing (EUL) from the World Health Organisation (WHO).
-
Australia Recognises Covaxin For Travel As It Eases Border Curbs
Earlier, the Therapeutic Goods Administration (TGA) had recommended that only the vaccines approved for use in Australia, and Covishield from India and Sinovac from China be recognised for the purposes of travel and other restrictions.
-
"Look Forward To Welcome Indian Students": Australia After Nod To Covishield
Australia today said it was looking forward to welcoming Indian students after its top medical regulator approved the Covishield vaccine manufactured by the Serum Institute of India for incoming international travellers.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
"India Still Has Some Covid": UK On Stricter Quarantine Rules For Indians
Although it is the same as the Oxford-AstraZeneca vaccine used in the UK's immunisation programme, Covishield wasn't approved until now. But the problem, the British envoy in India said, is India isn't on the 'green list' as Covid cases remain here.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covishield Booster At Rs 600 Plus Tax: Adar Poonawalla To NDTV
Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covid Vaccines Covishield, Covaxin Get Conditional Market Approval: Report
India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.
-
An Approval That Suggests Big Changes In Booster Policy Are Likely
Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after
-
Covishield, Covaxin Cleared For Market Approval By Expert Panel
An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said
-
With 1.25 Billion Jabs, Adar Poonawalla's Covishield Seeks Full Clearance
Adar Poonawalla's Serum Institute Of India has applied to the country's drug regulator and the health ministry for full approval of its COVID-19 vaccine Covishield, the chief executive said on Friday.
-
Drug Regulator Seeks More Data Over Approval For Covishield Booster: Report
An expert panel of India's central drug authority reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday.
-
Central Drug Regulator Approves Shelf Life Of COVID-19 Vaccines CoviShield, Covaxin, ZyCoV-D
The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.
-
'Awaiting Lifting Of Curbs...': New Zealand's Nod To Covaxin, Covishield
New Zealand has included Covaxin and Covishield to its list of eight approved vaccines, Indian High Commissioner to the country, Mukhtesh Pardeshi, said today.
-
Covishield, Covaxin Recognised By 96 Countries, Says Health Minister
Union Health Minister Mansukh Mandaviya said on Tuesday that 96 countries have recognised Covaxin and Covishield and both these COVID-19 vaccines have received emergency use listing (EUL) from the World Health Organisation (WHO).
-
Australia Recognises Covaxin For Travel As It Eases Border Curbs
Earlier, the Therapeutic Goods Administration (TGA) had recommended that only the vaccines approved for use in Australia, and Covishield from India and Sinovac from China be recognised for the purposes of travel and other restrictions.
-
"Look Forward To Welcome Indian Students": Australia After Nod To Covishield
Australia today said it was looking forward to welcoming Indian students after its top medical regulator approved the Covishield vaccine manufactured by the Serum Institute of India for incoming international travellers.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
"India Still Has Some Covid": UK On Stricter Quarantine Rules For Indians
Although it is the same as the Oxford-AstraZeneca vaccine used in the UK's immunisation programme, Covishield wasn't approved until now. But the problem, the British envoy in India said, is India isn't on the 'green list' as Covid cases remain here.
